These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22915941)

  • 1. Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.
    Dalby RN; Eicher J; Zierenberg B
    Med Devices (Auckl); 2011; 4():145-55. PubMed ID: 22915941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
    Hodder R; Price D
    Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the development of Respimat Soft Mist Inhaler.
    Dalby R; Spallek M; Voshaar T
    Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Respimat
    Iwanaga T; Tohda Y; Nakamura S; Suga Y
    Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
    Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
    J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.
    Panos RJ
    Int J Chron Obstruct Pulmon Dis; 2013; 8():221-30. PubMed ID: 23658481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease.
    Ferguson GT; Dalby RN
    Postgrad Med; 2018 Aug; 130(6):515-522. PubMed ID: 29972656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
    Delvadia RR; Longest PW; Hindle M; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat((R)) Soft Misttrade mark Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma.
    Vincken W; Bantje T; Middle MV; Gerken F; Moonen D
    Clin Drug Investig; 2004; 24(1):17-28. PubMed ID: 17516687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
    Pitcairn G; Reader S; Pavia D; Newman S
    J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
    Brand P; Hederer B; Austen G; Dewberry H; Meyer T
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Respimat Soft Mist inhaler in COPD patients.
    Anderson P
    Int J Chron Obstruct Pulmon Dis; 2006; 1(3):251-9. PubMed ID: 18046862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Environmental Impact of the Reusable Respimat
    Hänsel M; Bambach T; Wachtel H
    Adv Ther; 2019 Sep; 36(9):2487-2492. PubMed ID: 31317391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
    Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.
    Pavia D; Moonen D
    J Aerosol Med; 1999; 12 Suppl 1():S33-9. PubMed ID: 10623340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosol Plumes of Inhalers Used in COPD.
    Wachtel H; Emerson-Stadler R; Langguth P; Hohlfeld JM; Ohar J
    Pulm Ther; 2024 Mar; 10(1):109-122. PubMed ID: 38194194
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Mehri R; Alatrash A; Ogrodnik N; Matida EA; Fiorenza F
    J Aerosol Med Pulm Drug Deliv; 2021 Aug; 34(4):242-250. PubMed ID: 33170059
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
    Kässner F; Hodder R; Bateman ED
    Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.